My understanding is that if AstraZeneca succeed with AZD9291, it will overtake Roche's Tarceva as first line drug for NSCLC and become a huge threat to Roche's future revenue, then why would they be willing to help AstraZenenca with AZD9291 development? I wonder if the Roche is aware of the study conducted by the folks at Genentech on the combination of Tarceva + Ponatinib for addressing mutation issue? Thanks!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.